C1-Esterase Inhibitor Complement Inhibition NMO Relapse Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are inadequate in preventing relapses and reducing cumulative disability, as they do not effectively address the inflammatory damage to the central nervous system.
Innovation Solution
Administration of C1-esterase inhibitor (C1-INH), either alone or in combination with other agents like plasmapheresis and immunoglobulin preparations, during acute attacks to inhibit complement immune system activation and reduce neurologic dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (steroids, plasmapheresis, immunoglobulin) are used for NMO, then acute attacks can be managed, but relapses continue to occur and cumulative disability increases
Solution Approach 1:
The patent changes the therapeutic parameter by introducing complement pathway inhibition through C1-esterase inhibitor (C1-INH) administration. This targets a specific pathogenic mechanism (complement activation) that differs from conventional steroid-based treatments, thereby improving relapse prevention and reducing cumulative disability without increasing treatment duration or frequency
Solution Approach 2:
C1-esterase inhibitor acts as an intermediary substance that mediates between the autoimmune attack and tissue damage. By inhibiting complement activation, C1-INH blocks the harmful effects of autoantibodies against aquaporin-4, reducing neurologic deficits and preventing relapses while allowing patients to maintain functional independence
2Reliability
If long-term immunosuppressive therapy is used to prevent relapses, then disease progression may be slowed, but treatment complexity and potential side effects increase
Solution Approach 1:
The patent applies partial action by using C1-esterase inhibitor at specific dosages and durations targeted at acute relapse prevention rather than lifelong immunosuppression. This partial approach addresses the specific problem of relapse prevention without the excessive complexity and cumulative side effects of long-term multiple agents therapy
Solution Approach 2:
The patent extracts the complement activation pathway as a specific target for intervention, separating it from the complex web of immune mechanisms. By focusing solely on inhibiting complement (through C1-INH), the treatment simplifies the overall therapeutic strategy compared to multi-agent immunosuppressive regimens that target multiple pathways simultaneously
3Object-affected harmful factors
If aggressive treatment during acute attacks is administered, then neurologic damage can be reduced, but treatment duration and resource consumption increase
Solution Approach 1:
The patent applies preliminary action by administering C1-esterase inhibitor at the onset or early in the acute attack period, before complement-mediated damage fully develops. This timing optimizes the reduction of neurologic damage while minimizing treatment duration, as the inhibitor prevents rather than reverses established damage
Solution Approach 2:
The patent converts the harmful complement activation pathway into a beneficial target for therapy. By identifying complement as the harmful effector mechanism and using C1-INH to block it, the treatment transforms a previously uncontrollable destructive process into a manageable and reversible condition, reducing neurologic damage without requiring prolonged treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Early and short-term treatment with C1-INH, such as CINRYZE®, reduces damage to the nervous system and provides a durable reduction in disease burden, improving outcomes for NMO and NMOSD patients by minimizing neurologic deficits and delaying disease progression.
Implementation Method 1
administering, during an active CNS attack, a therapeutically effective amount of C1-esterase inhibitor (C1-INH) alone or in combination with other agents useful for treatment of such CNS disorders
Data Source
AI summary
Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.